Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
about
Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin forExploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responsesItraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancerOptimizing the management of advanced non-small-cell lung cancer: a personal viewAnticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesisCombination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamicsMolecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinomaAngiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).Clinical development of nintedanib for advanced non-small-cell lung cancerThe distinctive nature of adenocarcinoma of the lungNovel targeted agents for the treatment of lung cancer in ChinaEfficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsThe Evolution of Therapies in Non-Small Cell Lung CancerIncidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trialsThe impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic reviewNovel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancerK-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive ValuePostprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancerMaintaining clarity: Review of maintenance therapy in non-small cell lung cancerEpigenetics of lung cancerMaintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old ideaTargeting receptor tyrosine kinases in gastric cancerPractical management of bevacizumab-related toxicities in glioblastomaGefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic reviewRole of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic reviewTailored therapy in lung cancerCurrent status of oncothermia therapy for lung cancerEGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancerBiomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.The role of surgical intervention in lung cancer with carcinomatous pleuritisPersonalized treatment of advanced non-small-cell lung cancer in routine clinical practiceHow old is "too old" for translational research?Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation TherapyCarboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancerIncreased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials.Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.More sound cancer therapy biomarker development with active noise control.Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.Strategies for modern biomarker and drug development in oncology.
P2860
Q21261297-262E4409-88BB-4016-A49E-1CB8A12769ABQ24604495-5D7F1E57-C7AB-48E1-B140-0CD415EC18EAQ24632703-DDF4C879-35BB-451A-9878-60D433FE212BQ24656144-289306DB-B74E-4390-9E5C-86C52E942100Q26740812-6E723DE4-41E3-49AD-8A0C-1253D552BB7FQ26746067-7810B90C-2C8D-4C1B-9402-CC8DEA73C9A1Q26767182-23C851A2-2879-477A-878B-5051C7FB833FQ26775394-577B75C7-652E-4373-ABC7-4247C5561938Q26775822-256015B5-A3F2-4946-BDFC-B09ADEF33B5CQ26781159-301CC907-A77C-44C4-8A0D-8642D01B5098Q26786580-66EC1FFD-AD84-4BBD-85B5-112FF6E4736DQ26786618-E8864345-1148-4BAA-BFBC-3D3F3E605C40Q26786932-D16344CD-2939-48F7-B7E1-0590B70ABC1BQ26796456-3194ABAA-DFE6-4325-BEFC-ABDE814C9C1CQ26824086-14631151-DB71-4706-AC1E-C3AA170BB893Q26827571-463D0303-1FAF-4944-9FDC-1E9121012DEEQ26829425-D00496AD-2BD8-4933-93C3-BCA5D8226553Q26829939-71CC0ED9-5288-49AF-A725-20F4EB3A729BQ26996389-840915C9-950F-4262-B8A2-71AC1DAE8052Q26996766-5D6C0FA7-D1F8-46EC-B0B9-6F0D03D26252Q27011282-91037FA3-88ED-48B0-95A2-20F0B16615A7Q27013050-26E3A9F9-3408-4086-8334-0250F0BDEB52Q27015852-BF6AC612-C3A9-418C-B6A8-333E80CBC0E6Q27023100-68A5CD27-D71B-46D2-A929-B71D31F38251Q27025724-11DDE40C-0C1C-46D4-BD7F-77000B7C9203Q27026316-F65A0611-D2B5-464B-92A0-13D0B3E19E39Q27690889-475E946B-799B-4D66-B44C-4E029E61C2CFQ27852543-7FAE454F-84BA-4FF9-95F8-0889BC35F9F7Q27853358-42A719AD-5B82-4D74-91B9-D2293C388757Q28068169-C30DE0C6-ADE7-438D-AF07-1025AD6223C5Q28075800-A1B395EF-3B67-4215-A233-1DA6CCACBA3AQ28082652-1E8AE026-1F3C-4CCB-A0FE-461ED24A7F0EQ28086904-6E9249A6-9DA2-4BA2-9EDF-38933FB67176Q28265589-94D3B37E-6D92-41FF-A356-20BABFD318A7Q30248296-10AECFEB-6E4E-4C5F-93C0-C951A096AD75Q30249335-0DC75992-CBB9-49CF-9C9F-9A64F0B891DCQ30442454-14040A73-5003-4CEB-9D28-D2AFA5B4AB4FQ30469815-15F9C539-63C0-40A5-913D-79B01E02FC1DQ30471456-9A8FA346-AD71-476A-9E3B-01E92BFDA5C8Q30590270-BF703078-ED29-4E99-9801-749A1B37BFBA
P2860
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase III trial of cisplatin p ...... small-cell lung cancer: AVAil.
@ast
Phase III trial of cisplatin p ...... small-cell lung cancer: AVAil.
@en
Phase III trial of cisplatin p ...... small-cell lung cancer: AVAil.
@nl
type
label
Phase III trial of cisplatin p ...... small-cell lung cancer: AVAil.
@ast
Phase III trial of cisplatin p ...... small-cell lung cancer: AVAil.
@en
Phase III trial of cisplatin p ...... small-cell lung cancer: AVAil.
@nl
prefLabel
Phase III trial of cisplatin p ...... small-cell lung cancer: AVAil.
@ast
Phase III trial of cisplatin p ...... small-cell lung cancer: AVAil.
@en
Phase III trial of cisplatin p ...... small-cell lung cancer: AVAil.
@nl
P2093
P921
P356
P1476
Phase III trial of cisplatin p ...... small-cell lung cancer: AVAil.
@en
P2093
Christian Manegold
Joachim von Pawel
Jörg Mezger
Martin Reck
Natasha Leighl
Nicola Moore
Petr Zatloukal
Venice Archer
Vera Gorbounova
Vera Hirsh
P304
P356
10.1200/JCO.2007.14.5466
P407
P577
2009-02-02T00:00:00Z